The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: A randomized controlled study

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 1, 2002, Pages 195-202

  Yavuz, Melek N ^a   Yavuz, A Aydin ^a   Aydin, Fazil ^a   Can, Gamze ^a   Kavgaci, Halil ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Octreotide; Pelvic radiation therapy; Radiation induced diarrhea

Indexed keywords

CHEMOTHERAPY; ELECTROLYTES; FLUIDS; PATIENT MONITORING; PHOTONS; TOXICITY;

RADIATION ENTERITIS;

ONCOLOGY;

ATROPINE PLUS DIPHENOXYLATE; ELECTROLYTE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE CONTROL; DOSE CALCULATION; DRUG EFFICACY; FEMALE; HUMAN; INTESTINE; MAJOR CLINICAL STUDY; MALE; PARENTERAL NUTRITION; PHOTON; PRIORITY JOURNAL; RADIATION DOSE; RADIATION ENTEROPATHY; RANDOMIZED CONTROLLED TRIAL; TIME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIDIARRHEALS; DIARRHEA; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PROSPECTIVE STUDIES; RADIOTHERAPY;

EID: 0036716740     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02870-5     Document Type: Article

References (54)

1. Tolerance of the intestine to radiation therapy
2. Radiation therapy tolerance limits. For one or for all? Janeway Lecture
3. Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma
4. Olsalazine is contraindicated during pelvic radiation therapy: Results of a double-blind, randomized clinical trial
5. Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome
6. Radiation-induced enteropathy
7. Constipation and diarrhea
8. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analog
9. Clinical experience of somatostatin analog (compound 201-995, Sandostatin) as an antidiarrheal agent in VIPoma
10. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea
11. Effect of a long-acting somatostatin analog (SMS 201-995) in a patient with pancreatic cholera
12. Effects of a long-acting somatostatin analog in patients with severe ileostomy diarrhoea
13. Long-term results of octreotide-therapy in severe dumping syndrome
14. Prolonged treatment of Zollinger-Ellison syndrome by long-acting somatostatin
15. Efficacy of the somatostatin analog octreotide in the treatment of two patients with refractory diabetic diarrhea
16. The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation
17. Octreotide in the management of treatment-related diarrhoea
18. Octreotide acetate in refractory bone marrow transplant-associated diarrhea
19. Sandostatin (S) therapy for chemotherapy (CT) and radiotherapy (RT) related diarrhea (D)
20. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial
21. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy
22. Octreotide acetate in the treatment of fluorouracil-induced diarrhea
23. Octreotide in the treatment of severe chemotherapy-induced diarrhea
24. Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin
25. Octreotide acetate in refractory bone marrow transplant-associated diarrhea
26. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: Dose finding study and evaluation of efficacy
27. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea
28. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients
29. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma
30. Somatostatin attenuates ischemic intestinal injury
31. The synthetic somatostatin analog, octreotide, ameliorates acute and delayed intestinal radiation injury
32. Effects of SMS 201-995 on basal and stimulated pancreatic secretion in rats
33. Octreotide
34. Somatostatin stimulates sodium and chloride absorption in the rabbit ileum
35. Effect of the somatostatin analog sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men
36. Morphologic response of the mucosa of human small intestine to x-ray exposure
37. Radiation-induced intestinal injury
38. Radiation injuries of the gastrointestinal tract
39. Colonic histologic changes induced by 5-fluorouracil
40. The Franz Buschke lecture: Late effects of chemotherapy and radiation therapy. A new hypothesis
41. Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats
42. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid
43. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation
44. The role of luminal contents in radiation enteritis
45. Injurious effect of pancreatic secretions on postradiation enteropathy
46. Receptor activity and pharmacological potency of a series of narcotic analgesic, antidiarrheal and neurological drugs
47. Diarrhea in terminally ill patients: Pathophysiology and treatment
48. Effect of a long-acting somatostatin analog (SMS 201-995) on postprandial gastric emptying of 99mTc-tin colloid and mouth-to-caecum transit time in man
49. Somatostatin analogs suppress the inflammatory reaction in vivo
50. Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo
51. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis
52. Recommended guidelines for the treatment of chemotherapy-induced diarrhea
53. Multiple G-protein-dependent pathways mediate the antisecretory effects of somatostatin and clonidine in the HT29-19A colonic cell line
54. Response to increasing doses of octreotide in a patient with carcinoid syndrome